IMC-18F1
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for IMC-18F1, covering 2010-09-30 to 2019-07-02. Get the full timeline:
Most recent: Clinical Trial Update: Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma [Phase 2]